Could This Be the Future of Herpes Treatment?
With all the cuts to healthcare funding in the United States, it’s natural to wonder how this might impact your access to care. If you’re living with herpes and often wonder when—or if—we’ll see a cure, these concerns might feel especially pressing.
So what’s actually happening in herpes research right now?
The NIH Plan is Still Alive
Previously, I’ve shared my concerns about what might happen to the NIH Strategic Plan for Herpes Research. As of May 2025, the plan has been reviewed and updated. I’ll be conducting an in-depth analysis of any changes, but here’s what matters most right now:
The plan still exists
It was recently updated, indicating it remains a priority
While we wait for more details about the research plan, there’s promising news from the pharmaceutical world.
A New Clinical Trial Begins
This week, Assembly Biosciences announced they’ve dosed the first participant in a clinical trial for ABI-1179, a new long-acting herpes treatment. This marks the beginning of Phase 1b, which is enrolling people with recurrent genital HSV-2.
What Makes ABI-1179 Different?
Unlike current antivirals that require daily dosing (e.g., acyclovir or valacyclovir), ABI-1179 is designed to be taken once per week. It belongs to a newer class of treatments called helicase-primase inhibitors, which target a different part of the herpes virus replication process.
What Does This Trial Involve?
The study is currently in Phase 1b, still early in the research process, but now testing the drug’s performance in people living with recurrent genital herpes (HSV-2). Over 29 days, participants receive weekly oral doses.
Researchers are measuring several key outcomes, including:
Safety and side effects of the drug
How the drug behaves in the body
Antiviral activity, including:
Changes in viral shedding
HSV-2 DNA levels from anogenital swabs
Lesion recurrence and duration
This data will inform appropriate dosing for future studies.
Important Note: ABI-1179 remains investigational and hasn’t been approved by the FDA or any regulatory body. However, this trial represents meaningful progress toward more effective, convenient herpes treatments. For more information about this Phase 1a/b trial, or to learn about enrollment opportunities, please click here.
Is a Cure on the Horizon?
Herpes treatments have remained largely unchanged for decades, with little hope for improvement beyond empty promises from wellness grifters. While this trial brings encouraging news about potential improvements to long-term herpes management, it doesn’t indicate a cure is near, nor is that the focus or goal of this particular study.
So no, it’s not a cure, but it is progress in a field that feels like it’s been frustratingly stagnant.
Want to stay updated on future herpes research developments? Subscribe to get these updates delivered to your inbox.
Subject: Healing, Disclosure & the Future of Health: A Thought to Consider
Dear Emily,
Thank you for your continued advocacy and honesty around herpes care and public awareness. Your writing on the stagnation in treatment is not only informative, but incredibly validating to those who feel ignored or underserved by the medical establishment.
While mainstream science may not yet offer a cure, I wanted to share a perspective from a different vantage point — one rooted in disclosure, off-planet technologies, and the belief that our understanding of healing may soon experience a dramatic paradigm shift.
There are whistleblowers and experiencers who have spoken openly about Med-Beds — advanced regenerative healing technologies reportedly used in covert space programs. Colonel Randy Cramer, a military insider, has described these technologies in detail: machines capable of cellular repair, organ regeneration, and even full body restoration. His colleague, Kendra Soleil, is a passionate advocate for consciousness expansion and has worked to bring awareness to these developments as part of humanity’s shift into galactic-level medicine and ethics.
Elena Kapulnik, a multidimensional contactee and speaker, has also testified to the use of advanced healing systems aboard ships and within higher-density societies — where frequency, intention, and spiritual alignment are core to the healing process.
And then there’s Andrew D. Basiago, an attorney and time travel experiencer who was involved in Project Pegasus, a classified U.S. government initiative involving teleportation and chrono-navigation. He’s shared detailed accounts of traveling through time and even to Mars, and has announced his candidacy for President of the United States in 2028 — a campaign centered around truth-telling, government disclosure, and technological liberation.
I realize this may sound far removed from the grounded, clinical dialogue around public health — but perhaps that’s part of the story. Maybe the real progress is already here, waiting to be acknowledged, declassified, and responsibly shared.
Your work is important, and I believe you are part of a generation asking the right questions. Hope doesn’t have to come only from new drugs — it can also come from expanding what we consider possible, and listening to those whose voices challenge the limits of accepted reality.
Thank you again for all you do. Please keep going.